title: [Inhaled medication and inhalation devices for lung disease].
abstract: Nebulized antibiotic therapy is an attractive therapeutic option given the high concentration obtained from the drug at the site of infection, minimizing the adverse effects and possible drug interactions. Inhalation of drugs as treatment of cystic fibrosis (CF) related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. Other limited areas of experience in this field are lung transplant recipients, immunosuppressed patients, bronchiectasis and ventilated patients. In this review document we analyse the current status of the inhaled medications, their modes of administration and indications and their results as well as side effects. Specifically we address antibiotics, and additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Several factors contribute to a highly variable pulmonary drug deposition as the devices, the physical properties of the administered antimicrobial agent, the type of respiratory disease and the inhalation technique. Despite many clinicians have obtained a valuable experience from the aerosolized administration of antimicrobials and persuaded of their efficacy and safety. However, RCTs out of CF are needed to answer important clinical questions, such as what is the appropriate dose, the optimal delivery device, the optimal way of drug administration, as well as the exact therapeutic role and pharmacokinetic profile of aerosolized drug.
authors.affiliation: Amparo Solé, Hospital Universitari i Politècnic La Fe, Avinguda de Fernando Abril Martorell, nº 106, 46026 Valencia, Spain. sole_amp@gva.es.
authors.forename: Amparo
authors.initials: A
authors.lastname: Solé
authors.forename: Rosa Ma
authors.initials: RM
authors.lastname: Girón
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D003550:Cystic Fibrosis / Q000150:complications; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D009330:Nebulizers and Vaporizers
chemical_list: D000336:Aerosols